Clinical Trials Browser

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

NCT04427228 2023-08-28

MIGRAINE

Phase 2 Withdrawn

CNS

Brain Neoplasms

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04650490 2023-03-02

STICk-IM-NSCLC

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04909515 2022-09-01

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2 Withdrawn

CNS

Neuroblastoma

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03868423 2022-02-18

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Phase 2 Withdrawn

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT03234309 2021-11-10

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

Phase 2 Withdrawn

CNS

Brain Neoplasms

NCT02283944 2021-09-20

TMS Electrochemotherapy for Glioblastoma Multiforme

Phase 2 Withdrawn

CNS

Glioblastoma

NCT03688568 2021-02-12

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Phase 2 Withdrawn

CNS

Neurofibroma, Plexiform

NCT03506139 2020-09-09

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Phase 2 Withdrawn

CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT03014804 2020-07-24

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNSSarcoma

Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT03637868 2020-05-06

ERIBRAIN

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma, Glioma

NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Phase 2 Withdrawn

CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

NCT00814593 2019-05-10

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Phase 2 Withdrawn

CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT00621036 2018-11-26

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Phase 2 Withdrawn

CNSDermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 2 Withdrawn

CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT02014545 2018-07-05

Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01788280 2018-02-07

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Phase 2 Withdrawn

CNS

Glioblastoma

NCT01782976 2018-01-19

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Phase 2 Withdrawn

CNS

Glioblastoma, Recurrence

NCT02977689 2017-12-20

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Phase 2 Withdrawn

CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT02987010 2017-10-11

Phase 2 Study of IDH305 in Low Grade Gliomas

Phase 2 Withdrawn

CNS

Glioma

NCT01736800 2017-09-19

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Phase 2 Withdrawn

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

Phase 2 Withdrawn

CNS

Medulloblastoma, Meningioma, Neuroblastoma

NCT02425072 2017-08-10

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01413438 2017-07-02

Bevacizumab With or Without Surgery for Adult Glioblastomas

Phase 2 Withdrawn

CNS

Brain Neoplasms, Glioblastoma

NCT02876003 2017-02-24

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Phase 2 Withdrawn

CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

NCT01445691 2016-05-17

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Phase 2 Withdrawn

CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Phase 2 Withdrawn

CNS

Glioma

Clinical Trials

A Study of ONC201 for Refractory Meningioma

Abemaciclib + Pembrolizumab In Glioblastoma

PARAMETer

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

18F-Fluciclovine PET and Multiparametric MR Imaging

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

STRIDER

89Zr-RO5323441 PET Imaging in Glioblastoma

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

The Addition of Chloroquine to Chemoradiation for Glioblastoma,

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

MIGRAINE

PROTECT

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

PUTNET

STICk-IM-NSCLC

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

NeraBrain

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

TMS Electrochemotherapy for Glioblastoma Multiforme

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

ERIBRAIN

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Phase 2 Study of IDH305 in Low Grade Gliomas

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Dosimetry Guided PRRT With 90Y-DOTATOC

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

Bevacizumab With or Without Surgery for Adult Glioblastomas

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

MK-2206 for Recurrent Malignant Glioma